Nanoligent
Barcelona
About Nanoligent
Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. We are dedicated to drug design and development of targeted-therapeutic biologics .Nanoligent mision is to improve the life of patients by designing new medicines that selectively target the cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $17.9M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2025)
- Website: nanoligent.com
Industries & Categories
Biotechnology, Nanotechnology, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/nanoligent-96051 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.